NEWS

News

November

09/11/2020

Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session (Immunotherapy Stream) on November 10 with the title: Immunocytokines with "Activity on Demand".
Prof. Dario Neri will also give a Lecture in the Antibody-Drug Conjugates Session (Oncology Stream) on November 10 with the title: Antibody-Drug Conjugates (ADCs) and Small-Molecule Drug Conjugates (SMDCs): A Comparative Analysis.
 

02/11/2020

Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit from November 2 to 5, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Lecture with the title: Cancer Therapy Using Antibody-Cytokine Fusion Proteins.
 

October

08/10/2020

Philogen announces publication of malignant brain tumor study results in Science Translational Medicine.

  Press Release

September

15/09/2020

Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020.
Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative Evaluation”.

August

20/08/2020

Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here.

  Always ask the important questions

July

17/07/2020

Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients”
Link to Paper
 

June

26/06/2020

Philogen received clinical trial authorisation with NIDLEGYTM in nonmelanoma skin cancer

  NIDLEGY authorisation in nonmelanoma skin cancer

24/06/2020


Philogen received combination pack approval for NidlegyTM

  PR Nidlegy Combination Pack Approval

April

28/04/2020

Philogen announces Option Exercise by Janssen

  PR Option Exercise by JANSSEN
x

By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy
X